

# Nilofer S Azad

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6995311/publications.pdf>

Version: 2024-02-01

43  
papers

7,234  
citations

346980

22  
h-index

274796

44  
g-index

45  
all docs

45  
docs citations

45  
times ranked

13941  
citing authors

#	ARTICLE	IF	CITATIONS
1	Current Surgical Management Strategies for Colorectal Cancer Liver Metastases. <i>Cancers</i> , 2022, 14, 1063.	1.7	24
2	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2022, 40, 1231-1258.	0.8	96
3	Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. <i>JCO Precision Oncology</i> , 2022, , .	1.5	19
4	Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4336-4345.	3.2	3
5	Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. <i>Cancer Control</i> , 2021, 28, 107327482110099.	0.7	4
6	A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint. <i>Clinical Epigenetics</i> , 2021, 13, 25.	1.8	11
7	Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma. <i>JCI Insight</i> , 2021, 6, .	2.3	10
8	Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy. <i>Cancer Immunology Research</i> , 2021, 9, 1187-1201.	1.6	11
9	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2021, 22, 1290-1300.	5.1	178
10	Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 837-862.	2.7	8
11	Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1278-1286.	3.2	35
12	Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. <i>Oncolimmunology</i> , 2021, 10, 2001159.	2.1	10
13	High performance methylated DNA markers for detection of colon adenocarcinoma. <i>Clinical Epigenetics</i> , 2021, 13, 218.	1.8	5
14	A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. <i>Cancer Medicine</i> , 2020, 9, 1485-1494.	1.3	48
15	A Phase I Study of Dinaciclib in Combination With MK-0752 in Patients With Advanced Pancreatic Cancer. <i>Clinical and Translational Science</i> , 2020, 13, 1178-1188.	1.5	23
16	Response to McNamara's comment on "Cost-utility of colorectal cancer screening at age 40 years old for average-risk patients" by Azad et al. <i>Preventive Medicine</i> , 2020, 139, 106181.	1.6	0
17	Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 4842-4851.	3.2	72
18	Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma). <i>Chinese Clinical Oncology</i> , 2020, 9, 2-2.	0.4	38

#	ARTICLE	IF	CITATIONS
19	Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. <i>Lancet Oncology</i> , The, 2020, 21, e135-e145.	5.1	155
20	Cost-utility of colorectal cancer screening at 40 years old for average-risk patients. <i>Preventive Medicine</i> , 2020, 133, 106003.	1.6	21
21	Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3557-3564.	3.2	4
22	Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 711-720.	3.7	161
23	MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity. <i>PLoS ONE</i> , 2019, 14, e0224600.	1.1	23
24	An analysis of genetic heterogeneity in untreated cancers. <i>Nature Reviews Cancer</i> , 2019, 19, 639-650.	12.8	139
25	Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma. <i>Radiation Oncology</i> , 2019, 14, 147.	1.2	14
26	Executive Summary of the American Radium Society Appropriate Use Criteria for Treatment of Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 591-605.	0.4	5
27	Executive Summary of the American Radium Society Appropriate Use Criteria for Local Excision in Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 977-993.	0.4	6
28	Readmission Adversely Affects Survival in Surgical Rectal Cancer Patients. <i>World Journal of Surgery</i> , 2019, 43, 2506-2517.	0.8	4
29	The DNA Damaging Revolution: PARP Inhibitors and Beyond. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 185-195.	1.8	144
30	A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors. <i>Cancer</i> , 2019, 125, 2837-2845.	2.0	17
31	Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival. <i>Cancer Immunology Research</i> , 2019, 7, 886-895.	1.6	171
32	PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. <i>JCI Insight</i> , 2019, 4, .	2.3	345
33	A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan. <i>Clinical Cancer Research</i> , 2018, 24, 6160-6167.	3.2	46
34	A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. <i>Gynecologic Oncology</i> , 2017, 144, 486-490.	0.6	47
35	The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. <i>British Journal of Cancer</i> , 2017, 116, 1402-1407.	2.9	54
36	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017, 357, 409-413.	6.0	4,945

#	ARTICLE	IF	CITATIONS
37	<i>GPX3</i> promoter methylation predicts platinum sensitivity in colorectal cancer. <i>Epigenetics</i> , 2017, 12, 540-550.	1.3	43
38	Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells. <i>PLoS ONE</i> , 2017, 12, e0176139.	1.1	30
39	Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1532-1539.	1.9	54
40	Analysis of fiducials implanted during EUS for patients with localized rectal cancer receiving high-dose rate endorectal brachytherapy. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 765-769.e1.	0.5	17
41	A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis. <i>Clinical Cancer Research</i> , 2015, 21, 68-76.	3.2	65
42	Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. <i>Modern Pathology</i> , 2015, 28, 1390-1399.	2.9	53
43	Mutational profiling of colorectal cancers with microsatellite instability. <i>Oncotarget</i> , 2015, 6, 42334-42344.	0.8	69